Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Assembly BiosciencesASMB -1.76%32 Days Sales Outstanding is 7.92 as of Mar. 2026, which is 78% below its 10-year median of 35.43. GuruFocus rates ASMB with a GF Score™ of 32/100. The stock has 3 warning signs investors should review. Among 836 Biotechnology companies, Assembly Biosciences ranks better than 97.13% on this metric.
The historical rank and industry rank for Assembly Biosciences's Days Sales Outstanding or its related term are showing as below:
ASMB'
s Days Sales Outstanding Range Over the Past 10 Years
Min: 0.55 Med: 35.43 Max: 92.03
Current: 4
During the past 13 years, Assembly Biosciences's highest Days Sales Outstanding was 92.03. The lowest was 0.55. And the median was 35.43.
ASMB's Days Sales Outstanding is ranked better than 97.13% of 836
companies
in the Biotechnology industry
Industry Median: 68.89
vs ASMB: 4.00
Assembly Biosciences's Days Sales Outstanding
increased
from Mar. 2025 (0.00) to Mar. 2026 (7.92).
Assembly Biosciences (NAS:ASMB) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
Assembly Biosciences Days Sales Outstanding Related Terms
Assembly Biosciences Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for Assembly Biosciences's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASMB vs ZURA, ARVN, ARTV: Days Sales Outstanding Comparison
For the Biotechnology subindustry, Assembly Biosciences's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Assembly Biosciences Days Sales Outstanding vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Assembly Biosciences's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Assembly Biosciences's Days Sales Outstanding falls into.
Assembly Biosciences Days Sales Outstanding Calculation
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Assembly Biosciences (ASMB) has a Days Sales Outstanding of 7.92 as of Mar. 2026. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Assembly Biosciences and its competitors. This is 78% below median its historical median of 35.43. Over the past decade, Assembly Biosciences' Days Sales Outstanding has ranged from 0.55 to 92.03. According to the industry distribution chart, Assembly Biosciences ranks #24 out of 836 companies in the Biotechnology industry, placing it in the top 2.9%.
Is Assembly Biosciences' Days Sales Outstanding too high?
Assembly Biosciences' current Days Sales Outstanding of 7.92 is 78% below median its 10-year median of 35.43. Over the past 10 years, this metric has ranged from a low of 0.55 to a high of 92.03. The Biotechnology industry median Days Sales Outstanding is 68.89. Assembly Biosciences' value of 7.92 is 88.5% below this industry median. Based on the distribution chart, Assembly Biosciences ranks #24 out of 836 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Assembly Biosciences has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Assembly Biosciences' Days Sales Outstanding compare to ZURA and ARVN?
According to the Biotechnology industry distribution chart, Assembly Biosciences ranks #24 out of 836 companies for Days Sales Outstanding. This places Assembly Biosciences in the top 3% of its industry — outperforming the majority of peers. The industry median Days Sales Outstanding is 68.89. Assembly Biosciences' value of 7.92 is 88.5% below this benchmark. Historically, Assembly Biosciences' own Days Sales Outstanding has ranged from 0.55 to 92.03 over the past decade. While the company's 10-year median is 35.43 vs. the industry median of 68.89, Assembly Biosciences has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Biotechnology company?
The median Days Sales Outstanding among Biotechnology companies is 68.89, based on 836 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Assembly Biosciences's current Days Sales Outstanding of 7.92 is 88.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Assembly Biosciences and its competitors. For the Biotechnology industry, the median Days Sales Outstanding is 68.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Assembly Biosciences's current Days Sales Outstanding is 7.92, which is 78% below median its own 10-year median of 35.43. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Assembly Biosciences stock overvalued right now?
Assembly Biosciences (ASMB) has a current Days Sales Outstanding of 7.92. The current Days Sales Outstanding is 7.92, which is 78% below median its 10-year median of 35.43 and 88.5% below the Biotechnology industry median of 68.89. Assembly Biosciences' overall GF Score™ is 32/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For Assembly Biosciences (ASMB), the current Days Sales Outstanding is 7.92 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Assembly Biosciences Inc is a clinical-stage biotechnology company. The Company's pipeline includes multiple clinical-stage investigational therapies, including: (1) two long-acting helicase-primase inhibitors (HPI) for the treatment of recurrent genital herpes; (2) an orally bioavailable hepatitis delta virus entry inhibitor; and (3) a potent next-generation capsid assembly modulator designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. The Company's pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) for the treatment of transplant-related herpesviruses.
32GF Score
Get the complete analysis for ASMB
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASMB has been successfully added to your 
